The Use of whole genome sequencing for tuberculosis public health activities in Australia: a joint statement of the National Tuberculosis Advisory Committee and Communicable Diseases Genomics Network

Authors

  • Ellen J Donnan New South Wales Tuberculosis Program, Health Protection New South Wales, Sydney, Australia
  • Ben J Marais The Children’s Hospital at Westmead, Sydney Childrens Hospital Network, Sydney, Australia; Sydney Infectious Diseases Institute (Sydney ID), University of Sydney, Sydney, Australia
  • Chris Coulter Communicable Diseases Branch, Queensland Department of Health, Brisbane, Australia; Queensland Mycobacterium Reference Laboratory, Pathology Queensland, Queensland Health, Brisbane, Australia
  • Justin Waring Western Australia Tuberculosis Control Program, North Metropolitan Health Service, Public Health Services, Perth, Western Australia
  • ivan Bastian SA Pathology, Adelaide, Australia
  • Deborah A Williamson Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Department of Infectious Diseases, Doherty Institute, University of Melbourne, Melbourne, Australia
  • Norelle L Sherry Microbiological Diagnostic Unti Public Health Laboratory, Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia; Department of Infectious Diseases, Austin Health, Melbourne, Australia
  • Katherine Bond Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
  • Vitali Sintchenko Sydney Infectious Diseases Institute (Sydney ID), University of Sydney, Sydney, Australia; Institute of Clinical Pathology and Medical Research – NSW Health Pathology, Sydney, Australia
  • Ella M Meumann Royal Darwin Hospital, Darwin, Australia; Menzies School of Health Research, Darwin, Australia
  • Kristy Horan Microbiological Diagnostic Unti Public Health Laboratory, Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia
  • Louise Cooley Department of Microbiology and Infectious Diseases, Royal Hobart Hospital, Hobart, Australia; University of Tasmania, Hobart, Australia
  • Justin T Denholm Department of Infectious Diseases, Doherty Institute, University of Melbourne, Melbourne, Australia; Victorian Tuberculosis Program, Melbourne Health, Melbourne, Australia

DOI:

https://doi.org/10.33321/cdi.2023.47.8

Keywords:

Mycobacterium tuberculosis, whole genome sequencing

Abstract

The public health utility of whole genome sequencing (WGS) for Mycobacterium tuberculosis includes genome-wide mutation analysis for genotypic drug susceptibility testing (DST), strain identification, differentiation of tuberculosis (TB) relapse from re-infection, transmission cluster detection to guide targeted public health responses and detection of laboratory cross contamination. This has the potential to optimise individual patient care and provide better targeted TB control measures compared to previous MIRU-VNTR genotyping methods. High resolution genotyping of TB should allow better targeting of contact tracing interventions and prevention strategies. WGS will be useful in programmatic evaluation of clinical and public health TB programs through the identification of relapse and cluster analyses to assess effectiveness of contact tracing activities.
Characterising pathogens using WGS is usually less laborious and less expensive than traditional typing methods, and laboratory costs will likely further decrease as it is probable that WGS will soon reduce the need for routine phenotypic DST. However, resource, infrastructure and workforce (including information technology infrastructure and bioinformatics support) has limited implementation of WGS in some jurisdictions, though all mycobacterial reference laboratories in Australia have implemented WGS to some extent. Pathogen genomic data need to be integrated with clinical and public health data to realise their full value. Effective reporting strategies still need to be established, including analyses of key clinical variables and reporting of clusters over time, as well as processes for communicating clusters in a timely manner for public health benefit.
NTAC and CDGN consider it a future requirement for all jurisdictions to have:
• access to prospective WGS of TB isolates;
• WGS results incorporated into routine laboratory reporting systems;
• WGS results reported to clinicians and public health programs;
• WGS results integrated into the routine TB surveillance system;
• routine cross jurisdictional comparison of WGS data; and
• continued education for public health staff and clinicians.
Through increasing capacity for identification of transmission risk and opportunities to intervene and prevent reactivation, WGS will be an increasingly valuable tool for TB control and elimination in Australia.

Downloads

Download data is not yet available.

References

Kwong JC, McCallum N, Sintchenko V, Howden BP. Whole genome sequencing in clinical and public health microbiology. Pathology. 2015;47(3): 199–210. doi: https://doi.org/10.1097/PAT.0000000000000235.

Armstrong GL, MacCannell DR, Taylor J, Carleton HA, Neuhaus EB, Bradbury RS et al. Pathogen genomics in public health. N Engl J Med. 2019;381(26):2569–80. doi: https://doi.org/10.1056/NEJMsr1813907.

Kizny Gordon A, Marais B, Walker TM, Sintchenko V. Clinical and public health utility of Mycobacterium tuberculosis whole genome sequencing. Int J Infect Dis. 2021;113(Suppl 1):S40–2. doi: https://doi.org/10.1016/j.ijid.2021.02.114.

Australian Government Department of Health and Aged Care. Tuberculosis – CDNA National Guidelines for Public Health Units. [Internet.] Canberra: Australian Government Department of Health and Aged Care; March 2022. Available from: https://www.health.gov.au/resources/publications/tuberculosis-cdna-national-guidelines-for-public-health-units.

Bastian I, Shephard L, Lumb R, National Tuberculosis Advisory Committee (NTAC). Revised guidelines for Australian laboratories performing mycobacteriology testing. Commun Dis Intell (2018). 2020. 44. doi: https://doi.org/10.33321/cdi.2020.44.2.

Hanekom M, van der Spuy GD, Gey van Pittius NC, McEvoy CRE, Hoek KGP, Ndabambi SL et al. Discordance between mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing and IS6110 restriction fragment length polymorphism genotyping for analysis of Mycobacterium tuberculosis Beijing strains in a setting of high incidence of tuberculosis. J Clin Microbiol. 2008;46(10):3338–45. doi: https://doi.org/10.1128/JCM.00770-08.

Tarashi S, Fateh A, Mirsaeidi M, Siadat SD, Vaziri F. Mixed infections in tuberculosis: the missing part in a puzzle. Tuberculosis (Edinb). 2017;107: 168–74. doi: https://doi.org/10.1016/j.tube.2017.09.004.

Wyllie DH, Robinson E, Peto T, Crook DW, Ajileye A, Rathod P et al. Identifying mixed Mycobacterium tuberculosis infection and laboratory cross-contamination during mycobacterial sequencing programs. J Clin Microbiol. 2018;56(11):e00923-18. doi: https://doi.org/10.1128/JCM.00923-18.

Asgharzadeh M, Ozma MA, Rashedi J, Poor BM, Agharzadeh V, Vegari A et al. False-positive Mycobacterium tuberculosis detection: ways to prevent cross-contamination. Tuberc Respir Dis (Seoul). 2020;83(3):211–7. doi: https://doi.org/10.4046/trd.2019.0087.

Genestet G, Tatai C, Berland JL, Claude JB, Westeel E, Hodille E et al. Prospective whole-genome sequencing in tuberculosis outbreak investigation, France, 2017–2018. Emerg Infect Dis. 2019;25(3):589–92. doi: https://doi.org/10.3201/eid2503.181124.

Satta G, Lipman M, Smith GP, Arnold C, Kon OM, McHugh TD. Mycobacterium tuberculosis and whole-genome sequencing: how close are we to unleashing its full potential? Clin Microbiol Infect. 2018;24(6):604–9. doi: https://doi.org/10.1016/j.cmi.2017.10.030.

Bainomugisa A, Pandey S, Donnan E, Simpson G, Foster JB, Lavu E et al. Cross-border movement of highly drug-resistant Mycobacterium tuberculosis from Papua New Guinea to Australia through Torres Strait Protected Zone, 2010–2015. Emerg Infect Dis. 2019;25(3):406–15. doi: https://doi.org/10.3201/eid2503.181003.

Meumann EM, Horan K, Ralph AP, Farmer B, Globan M, Stephenson E et al. Tuberculosis in Australia’s tropical north: a population-based genomic epidemiological study. Lancet Reg Health West Pac. 2021;15:100229. doi: https://doi.org/10.1016/j.lanwpc.2021.100229.

Lam C, Martinez E, Crighton T, Furlong C, Donnan E, Marais BJ et al. Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection. Int J Infect Dis. 2021;113(Suppl 1):S48–54. doi: https://doi.org/10.1016/j.ijid.2021.03.033.

Gurjav U, Outhred AC, Jelfs P, McCallum N, Wang Q, Hill-Cawthorne GA et al. Whole genome sequencing demonstrates limited transmission within identified Mycobacterium tuberculosis clusters in New South Wales, Australia. PLoS One. 2016;11(10):e0163612. doi: https://doi.org/10.1371/journal.pone.0163612.

Government of New South Wales Tuberculosis Program (NSW TB Program) Tuberculosis in NSW – Surveillance Report 2018. Sydney: Government of New South Wales Department of Health, Communicable Diseases Branch, NSW TB Program; December 2019. Available from: https://www.health.nsw.gov.au/Infectious/tuberculosis/Publications/2018-tb-report.pdf.

Nikolayevskyy V, Niemann S, Anthony R, van Soolingen D, Tagliani E, Ködmön C et al. Role and value of whole genome sequencing in studying tuberculosis transmission. Clin Microbiol Infect. 2019;25(11):1377–82. doi: https://doi.org/10.1016/j.cmi.2019.03.022.

Denholm J, Coulter C, Bastian I, NTAC. Defining a tuberculosis cluster or outbreak. Commun Dis Intell Q Rep. 2016;40(3):E356–9.

Shanmugam S, Bachmann NL, Martinez E, Menon R, Narendran G, Narayanan S et al. Whole genome sequencing based differentiation between re-infection and relapse in Indian patients with tuberculosis recurrence, with and without HIV co-infection. Int J Infect Dis. 2021;113(Suppl 1):S43–7. doi: https://doi.org/10.1016/j.ijid.2021.03.020.

Parvaresh L, Crighton T, Martinez E, Bustamante A, Chen S, Sintchenko V. Recurrence of tuberculosis in a low-incidence setting: a retrospective cross-sectional study augmented by whole genome sequencing. BMC Infect Dis. 2018;18(1):265. doi: https://doi.org/10.1186/s12879-018-3164-z.

Barac A, Karimzadeh-Esfahani H, Pourostadi M, Rahimi MT, Ahmadpour E, Rashedi J et al. Laboratory cross-contamination of Mycobacterium tuberculosis: a systematic review and meta-analysis. Lung. 2019;197(5):651–61. doi: https://doi.org/10.1007/s00408-019-00241-4.

Globan M, Lavender C, Leslie D, Brown L, Denholm J, Raios K et al. Molecular epidemiology of tuberculosis in Victoria, Australia, reveals low level of transmission. Int J Tuberc Lung Dis. 2016;20(5):652–8. doi: https://doi.org/10.5588/ijtld.15.0437.

Min J, Kim K, Choi H, Kang ES, Shin YM, An JY et al. Investigation of false-positive Mycobacterium tuberculosis culture tests using whole genome sequencing. Ann Thorac Med. 2019;14(1):90–3. doi: https://doi.org/10.4103/atm.ATM_184_18.

Kizny Gordon A, Tong SYC, Martinez E, Crighton T, Denholm JT, Sintchenko V. TB genomic surveillance and data sharing in recognising contamination events. Int J Tuberc Lung Dis. 2021;25(3):241–3. doi: https://doi.org/10.5588/ijtld.20.0740.

Wu J, Yang C, Lu L, Dai W. Detection of tuberculosis laboratory cross-contamination using whole-genome sequencing. Tuberculosis (Edinb). 2019;115:121–5. doi: https://doi.org/10.1016/j.tube.2018.10.012.

Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med. 2018;379(15):1403–15. doi: https://doi.org/10.1056/NEJMoa1800474.

Meehan CJ, Goig CA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol. 2019;17(9):533–45. doi: https://doi.org/10.1038/s41579-019-0214-5.

Ferdinand AS, Kelaher M, Lane CR, da Silva AG, Sherry NL, Ballard SA et al. An implementation science approach to evaluating pathogen whole genome sequencing in public health. Genome Med. 2021;13(1):121. doi: https://doi.org/1186/s13073-021-00934-7.

NTAC. The Strategic Plan for Control of Tuberculosis in Australia, 2016–2020: Towards Disease Elimination. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.10.

World Health Organization (WHO). Framework towards tuberculosis elimination in low-incidence countries. Geneva: WHO, Global Tuberculosis Programme; 18 March 2014. Available from: https://www.who.int/publications/i/item/9789241507707.

Marais BJ, Walker TM, Cirillo DM, Raviglione M, Abubakar I, van der Werf MJ et al. Aiming for zero tuberculosis transmission in low-burden countries. Lancet Respir Med. 2017;5(11):846–8. doi: https://doi.org/10.1016/S2213-2600(17)30382-X.

Downloads

Published

28/02/23

How to Cite

Donnan, Ellen J, Ben J Marais, Chris Coulter, Justin Waring, ivan Bastian, Deborah A Williamson, Norelle L Sherry, et al. 2023. “The Use of Whole Genome Sequencing for Tuberculosis Public Health Activities in Australia: A Joint Statement of the National Tuberculosis Advisory Committee and Communicable Diseases Genomics Network”. Communicable Diseases Intelligence 47 (February). https://doi.org/10.33321/cdi.2023.47.8.

Issue

Vol. 47 (2023)

Section

Policy and guidelines

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.